Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 2002, Circulation, 106 1994, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), Circulation, 89, 1333, 10.1161/01.CIR.89.3.1333 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X 2002, JAMA, 288, 2998, 10.1001/jama.288.23.2998 Sever, 2003, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Cannon, 2004, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 McNamara, 1995, Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated, Clin Chem, 41, 232, 10.1093/clinchem/41.2.232 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893 Dean, 2004, Can change in HDL-cholesterol reduce cardiovascular risk?, Am Heart J, 147, 966, 10.1016/j.ahj.2003.10.051 Rubins, 2000, Triglycerides and coronary heart disease, J Cardiovasc Risk, 7, 339, 10.1177/204748730000700507 Robins, 2003, Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT), Diabetes Care, 26, 1513, 10.2337/diacare.26.5.1513 Prueksaritanont, 2002, Effects of fibrates on metabolism of statins in human hepatocytes, Drug Metab Dispos, 30, 1280, 10.1124/dmd.30.11.1280 Pan, 2000, Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers, J Clin Pharmacol, 40, 316, 10.1177/00912700022008874 1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021 Canner, 1986, Fifteen year mortality in Coronary Drug Project patients, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090 Bays, 2003, Am J Cardiol, 91, 667, 10.1016/S0002-9149(03)00007-9 Law, 1994, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, 308, 367, 10.1136/bmj.308.6925.367 Law, 1994, An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990, Eur J Clin Nutr, 48, 305 Law, 2003, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke, BMJ, 326, 1423, 10.1136/bmj.326.7404.1423 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis, JAMA, 291, 1071, 10.1001/jama.291.9.1071 Waters, 2004, Treating to New Targets (TNT) Study, Am J Cardiol, 93, 154, 10.1016/j.amjcard.2003.09.031 Stemmermann, 1991, Serum cholesterol and mortality among Japanese-American men, Arch Intern Med, 151, 969, 10.1001/archinte.1991.00400050113021 Neaton, 1992, Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial, Arch Intern Med, 152, 1490, 10.1001/archinte.1992.00400190110021 Iso, 1994, Serum total cholesterol and mortality in a Japanese population, J Clin Epidemiol, 47, 961, 10.1016/0895-4356(94)90110-4 Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Davidson, 2002, Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia, J Am Coll Cardiol, 40, 2125, 10.1016/S0735-1097(02)02610-4 Ballantyne, 2003, Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia, Circulation, 107, 2409, 10.1161/01.CIR.0000068312.21969.C8 Shepherd, 1995, Prevention of coronary heart dis-ease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Jenkins, 2003, Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein, JAMA, 290, 502, 10.1001/jama.290.4.502 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711 Goldberg, 1998, Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels, Circulation, 98, 2513, 10.1161/01.CIR.98.23.2513 Haffner, 1999, Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels, Arch Intern Med, 159, 2661, 10.1001/archinte.159.22.2661 Pearson, 2003, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, 499, 10.1161/01.CIR.0000052939.59093.45 Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol, 81, 582, 10.1016/S0002-9149(97)00965-X